|
🐜
|
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
48 auth.
E. Cutsem,
A. Cervantes,
René Adam,
A. Sobrero,
J. V. Krieken,
D. Aderka,
E. Aguilar,
A. Bardelli,
A. Benson,
G. Bodoky,
F. Ciardiello,
A. D'Hoore,
E. Díaz-Rubio,
J. Douillard,
M. Ducreux,
...
A. Falcone,
A. Grothey,
T. Gruenberger,
K. Haustermans,
V. Heinemann,
P. Hoff,
C. Köhne,
R. Labianca,
P. Laurent-Puig,
B. Ma,
T. Maughan,
K. Muro,
N. Normanno,
P. Österlund,
P. Österlund,
W. Oyen,
D. Papamichael,
G. Pentheroudakis,
P. Pfeiffer,
T. Price,
C. Punt,
J. Ricke,
A. Roth,
R. Salazar,
W. Scheithauer,
H. Schmoll,
J. Tabernero,
J. Taieb,
S. Tejpar,
H. Wasan,
T. Yoshino,
A. Zaanan,
D. Arnold
|
11 |
2016 |
11
🐜
|
|
🦁
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
27 auth.
V. Heinemann,
L. V. von Weikersthal,
T. Decker,
A. Kiani,
U. Vehling‐Kaiser,
S. Al-Batran,
T. Heintges,
C. Lerchenmüller,
C. Kahl,
G. Seipelt,
F. Kullmann,
M. Stauch,
W. Scheithauer,
Jörg Hielscher,
M. Scholz,
...
S. Müller,
H. Link,
N. Niederle,
A. Rost,
H. Höffkes,
M. Moehler,
R. U. Lindig,
D. Modest,
Lisa Rossius,
T. Kirchner,
A. Jung,
S. Stintzing
|
10 |
2014 |
10
🦁
|
|
🐜
|
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
57 auth.
S. Al-Batran,
N. Homann,
C. Pauligk,
T. Goetze,
J. Meiler,
S. Kasper,
H. Kopp,
F. Mayer,
G. Haag,
K. Luley,
U. Lindig,
W. Schmiegel,
M. Pohl,
J. Stoehlmacher,
G. Folprecht,
...
S. Probst,
N. Prasnikar,
W. Fischbach,
R. Mahlberg,
J. Trojan,
M. Koenigsmann,
U. Martens,
P. Thuss-Patience,
M. Egger,
A. Block,
V. Heinemann,
G. Illerhaus,
M. Moehler,
M. Schenk,
F. Kullmann,
D. Behringer,
M. Heike,
D. Pink,
C. Teschendorf,
Carmen Löhr,
H. Bernhard,
G. Schuch,
V. Rethwisch,
L. F. V. Weikersthal,
J. Hartmann,
M. Kneba,
S. Daum,
K. Schulmann,
J. Weniger,
S. Belle,
T. Gaiser,
F. Oduncu,
M. Güntner,
W. Hozaeel,
Alexander Reichart,
E. Jäger,
T. Kraus,
S. Mönig,
W. Bechstein,
M. Schuler,
H. Schmalenberg,
R. Hofheinz
|
10 |
2019 |
10
🐜
|
|
🐜
|
The Liver Tumor Segmentation Benchmark (LiTS)
60 auth.
Patrick Bilic,
P. Christ,
Eugene Vorontsov,
G. Chlebus,
Hao Chen,
Q. Dou,
Chi-Wing Fu,
Xiao Han,
P. Heng,
J. Hesser,
S. Kadoury,
Tomasz K. Konopczynski,
Miao Le,
Chunming Li,
X. Li,
...
Jana Lipková,
J. Lowengrub,
H. Meine,
J. Moltz,
C. Pal,
M. Piraud,
Xiaojuan Qi,
Jin Qi,
M. Rempfler,
Karsten Roth,
A. Schenk,
A. Sekuboyina,
Ping Zhou,
Christian Hülsemeyer,
M. Beetz,
Florian Ettlinger,
Felix Grün,
Georgios Kaissis,
F. Lohöfer,
R. Braren,
J. Holch,
Felix O. Hofmann,
W. Sommer,
V. Heinemann,
C. Jacobs,
G. Mamani,
B. Ginneken,
G. Chartrand,
A. Tang,
M. Drozdzal,
Avi Ben-Cohen,
E. Klang,
M. Amitai,
E. Konen,
H. Greenspan,
Johan Moreau,
A. Hostettler,
L. Soler,
R. Vivanti,
Adi Szeskin,
N. Lev-Cohain,
J. Sosna,
Leo Joskowicz,
Bjoern H Menze,
ZENGMING SHEN
|
9 |
2019 |
9
🐜
|
|
🐬
|
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
W. Plunkett,
P. Huang,
Y. Z. Xu,
V. Heinemann,
R. Grunewald,
V. Gandhi
|
9 |
1995 |
9
🐬
|
|
🐜
|
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
11 auth.
Eric Van Cutsem,
H. Lenz,
C. Köhne,
V. Heinemann,
S. Tejpar,
I. Melezínek,
...
F. Beier,
C. Stroh,
P. Rougier,
J. Han van Krieken,
F. Ciardiello
|
9 |
2015 |
9
🐜
|
|
🐜
|
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †
13 auth.
D. Arnold,
B. Lueza,
J. Douillard,
M. Peeters,
H. Lenz,
A. Venook,
V. Heinemann,
E. Cutsem,
J. Pignon,
J. Tabernero,
...
A. Cervantes,
A. Cervantes,
F. Ciardiello
|
9 |
2017 |
9
🐜
|
|
🦁
|
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
20 auth.
V. Heinemann,
D. Quietzsch,
F. Gieseler,
M. Gonnermann,
H. Schönekäs,
A. Rost,
H. Neuhaus,
C. Haag,
M. Clemens,
B. Heinrich,
...
U. Vehling‐Kaiser,
M. Fuchs,
D. Fleckenstein,
W. Gesierich,
D. Uthgenannt,
H. Einsele,
A. Holstege,
A. Hinke,
A. Schalhorn,
R. Wilkowski
|
9 |
2006 |
9
🦁
|
|
🐢
|
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
9 auth.
S. Tejpar,
S. Stintzing,
F. Ciardiello,
J. Tabernero,
E. Van Cutsem,
F. Beier,
...
R. Esser,
H. Lenz,
V. Heinemann
|
9 |
2017 |
9
🐢
|
|
🐜
|
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
17 auth.
D. Goldstein,
R. El-Maraghi,
P. Hammel,
V. Heinemann,
V. Kunzmann,
J. Sastre,
W. Scheithauer,
S. Siena,
J. Tabernero,
Luis Teixeira,
...
G. Tortora,
J. Van Laethem,
R. Young,
D. Penenberg,
B. Lu,
A. Romano,
D. V. Von Hoff
|
9 |
2015 |
9
🐜
|
|
🐜
|
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
20 auth.
J. Franko,
Q. Shi,
J. Meyers,
T. Maughan,
R. Adams,
M. Seymour,
L. Saltz,
C. Punt,
M. Koopman,
C. Tournigand,
...
N. Tebbutt,
E. Díaz-Rubio,
J. Souglakos,
A. Falcone,
B. Chibaudel,
V. Heinemann,
J. Moen,
A. de Gramont,
D. Sargent,
A. Grothey
|
8 |
2016 |
8
🐜
|
|
🐢
|
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
J. Holch,
I. Ricard,
S. Stintzing,
D. Modest,
V. Heinemann
|
8 |
2017 |
8
🐢
|
|
🐢
|
Addressing the challenges of pancreatic cancer: future directions for improving outcomes.
9 auth.
M. Hidalgo,
S. Cascinu,
J. Kleeff,
R. Labianca,
J. Löhr,
J. Neoptolemos,
...
F. Real,
J. Van Laethem,
V. Heinemann
|
8 |
2015 |
8
🐢
|
